RT Journal Article
SR Electronic
T1 Association of Leukemia Target Genes <em>Tet2, Bcl2</em>, and <em>Slc23a2</em> in Vitamin C Pathways
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 333
OP 344
DO 10.21873/cgp.20138
VO 16
IS 5
A1 LI, JING
A1 ZHANG, WENQI
A1 LIU, WEIDONG
A1 RONG, JARRETT
A1 CHEN, YUHAN
A1 GU, WEIKUAN
A1 ZHANG, WEI
YR 2019
UL http://cgp.iiarjournals.org/content/16/5/333.abstract
AB Background: Vitamin C has been used in combination with several target genes in the treatment of leukemia. Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C. Materials and Methods: Using whole-genome expression profiles from mouse livers, the expression quantitative trait locus (eQTL), correlation matrix, and gene network graph were constructed with probes from each of these three genes and with their relative genes. The function of key genes was examined by their pathways and reported information. The results indicated that although direct correlations among their expression levels were not strong, alternative connecting pathways were discovered. By comparing the expression levels of one probe with known sequences from each of the three genes, we identified several key genes, induced myeloid leukemia cell differentiation protein (Mcl1), far upstream element-binding protein 1 (Fubp1), and tumor protein D52-like 2 (Tpd52l2), which play important roles in acute lymphocytic leukemia and acute myelocytic leukemia. In conclusion, Alternative pathways and key genes that connect Tet2, Bcl2, and Slc23a2 for their therapeutic applications with vitamin C were identified.